US5674908A
(en)
*
|
1993-12-20 |
1997-10-07 |
Life Technologies, Inc. |
Highly packed polycationic ammonium, sulfonium and phosphonium lipids
|
US6989434B1
(en)
|
1994-02-11 |
2006-01-24 |
Invitrogen Corporation |
Reagents for intracellular delivery of macromolecules
|
US6207646B1
(en)
*
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
FR2727679B1
(fr)
*
|
1994-12-05 |
1997-01-03 |
Rhone Poulenc Rorer Sa |
Nouveaux agents de transfection et leurs applications pharmaceutiques
|
US6383814B1
(en)
|
1994-12-09 |
2002-05-07 |
Genzyme Corporation |
Cationic amphiphiles for intracellular delivery of therapeutic molecules
|
US5795587A
(en)
|
1995-01-23 |
1998-08-18 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6008202A
(en)
*
|
1995-01-23 |
1999-12-28 |
University Of Pittsburgh |
Stable lipid-comprising drug delivery complexes and methods for their production
|
US6051429A
(en)
*
|
1995-06-07 |
2000-04-18 |
Life Technologies, Inc. |
Peptide-enhanced cationic lipid transfections
|
US20030069173A1
(en)
*
|
1998-03-16 |
2003-04-10 |
Life Technologies, Inc. |
Peptide-enhanced transfections
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6120794A
(en)
*
|
1995-09-26 |
2000-09-19 |
University Of Pittsburgh |
Emulsion and micellar formulations for the delivery of biologically active substances to cells
|
EP0904282B1
(de)
*
|
1996-04-12 |
2001-12-05 |
University Of Pittsburgh |
Neue kationische cholesterin derivate mit zyklischen polaren gruppen
|
US6258792B1
(en)
|
1996-04-12 |
2001-07-10 |
University Of Pittsburgh |
Cationic cholesteryl derivatives containing cyclic polar groups
|
WO1998000110A1
(en)
|
1996-07-03 |
1998-01-08 |
University Of Pittsburgh |
Emulsion formulations for hydrophilic active agents
|
US6251433B1
(en)
|
1996-08-13 |
2001-06-26 |
Chiron Corporation |
Polycationic polymers
|
US6210707B1
(en)
*
|
1996-11-12 |
2001-04-03 |
The Regents Of The University Of California |
Methods of forming protein-linked lipidic microparticles, and compositions thereof
|
WO1998020857A1
(en)
*
|
1996-11-12 |
1998-05-22 |
The Regents Of The University Of California |
Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
|
US5962429A
(en)
*
|
1996-11-22 |
1999-10-05 |
University Of Iowa |
Complexes of adenovirus with cationic molecules
|
US7083786B2
(en)
*
|
1997-04-03 |
2006-08-01 |
Jensenius Jens Chr |
MASP-2, a complement-fixing enzyme, and uses for it
|
US5948878A
(en)
*
|
1997-04-15 |
1999-09-07 |
Burgess; Stephen W. |
Cationic polymers for nucleic acid transfection and bioactive agent delivery
|
US6436708B1
(en)
|
1997-04-17 |
2002-08-20 |
Paola Leone |
Delivery system for gene therapy to the brain
|
US6197332B1
(en)
|
1997-08-13 |
2001-03-06 |
Chiron Corporation |
Lipid-conjugated polyamide compounds and related compositions and methods thereof
|
US7157098B1
(en)
*
|
1998-01-06 |
2007-01-02 |
Roman Perez-Soler |
Gene therapy of tumors using non-viral delivery system
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US7244714B1
(en)
*
|
1998-06-12 |
2007-07-17 |
Aradigm Corporation |
Methods of delivering aerosolized polynucleotides to the respiratory tract
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
AU772847B2
(en)
|
1998-11-12 |
2004-05-06 |
Invitrogen Corporation |
Transfection reagents
|
US6855549B1
(en)
|
1998-11-23 |
2005-02-15 |
The University Of Iowa Research Foundation |
Methods and compositions for increasing the infectivity of gene transfer vectors
|
DE69942782D1
(de)
*
|
1998-11-27 |
2010-10-28 |
Ucb Sa |
Zusammensetzungen und Verfahren zur Erhöhung der Knochenmineralisierung
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
BR0008227A
(pt)
*
|
1999-02-15 |
2001-10-30 |
Nippon Shinyaku Co Ltd |
Polinucleotìdeos de cadeia curta e método para apreparação dos mesmos
|
EP1156812A4
(de)
*
|
1999-02-23 |
2004-09-29 |
Isis Pharmaceuticals Inc |
Multipartikuläre formulierung
|
BR0008711A
(pt)
*
|
1999-03-02 |
2002-10-01 |
Liposome Co Inc |
Encapsulação de complexos bioativos em lipossomas
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
US20030104622A1
(en)
*
|
1999-09-01 |
2003-06-05 |
Robbins Paul D. |
Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
|
EP1229931A4
(de)
*
|
1999-10-07 |
2003-05-28 |
Corixa Corp |
Fusionsproteine aus mycobacterium tuberculosis
|
AU3366901A
(en)
*
|
1999-12-30 |
2001-07-16 |
Novartis Ag |
Novel colloid synthetic vectors for gene therapy
|
US6514523B1
(en)
|
2000-02-14 |
2003-02-04 |
Ottawa Heart Institute Research Corporation |
Carrier particles for drug delivery and process for preparation
|
PL209127B1
(pl)
|
2000-02-23 |
2011-07-29 |
Smithkline Beecham Biolog |
Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
|
WO2001062893A2
(en)
*
|
2000-02-25 |
2001-08-30 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AU2000239309A1
(en)
|
2000-03-29 |
2001-10-08 |
Dgi Biotechnologies Llc |
Insulin and igf-1 receptor agonists and antagonists
|
SI1542732T1
(sl)
|
2000-06-20 |
2010-01-29 |
Corixa Corp Csc The United Sta |
Fuzijski proteini Mycobacterium tuberculosis
|
WO2002000174A2
(en)
|
2000-06-28 |
2002-01-03 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US20040220100A1
(en)
*
|
2000-07-21 |
2004-11-04 |
Essentia Biosystems, Inc. |
Multi-component biological transport systems
|
ES2617692T3
(es)
*
|
2000-07-21 |
2017-06-19 |
Revance Therapeutics, Inc. |
Sistemas de transporte de agentes biológicos de múltiples componentes
|
DE10049010A1
(de)
*
|
2000-10-04 |
2002-04-18 |
Boehringer Ingelheim Int |
Transferrin-Polykation/DNS-Komplexe für die systemische Therapie von Tumorerkrankungen mit zytotoxischen Proteinen
|
AU2001294185B2
(en)
*
|
2000-10-04 |
2006-12-21 |
Kyowa Hakko Kirin Co., Ltd. |
Method of coating fine particles with lipid membrane
|
CA2437555A1
(en)
*
|
2001-02-01 |
2002-08-08 |
Yiyu Zou |
Stabilised polymeric aerosols for pulmonary gene delivery
|
US20030096414A1
(en)
*
|
2001-03-27 |
2003-05-22 |
Invitrogen Corporation |
Culture medium for cell growth and transfection
|
CA2445947A1
(en)
*
|
2001-04-30 |
2002-11-07 |
Targeted Genetics Corporation |
Lipid-comprising drug delivery complexes and methods for their production
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
WO2002094983A2
(en)
*
|
2001-05-16 |
2002-11-28 |
The Children's Hospital Of Philadelphia |
Dna-antibody complexes to enhance gene transfer
|
AU2002348163A1
(en)
*
|
2001-11-02 |
2003-05-19 |
Intradigm Corporation |
Therapeutic methods for nucleic acid delivery vehicles
|
CA2476755C
(en)
|
2001-12-17 |
2014-08-26 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
WO2003066068A1
(en)
*
|
2002-02-01 |
2003-08-14 |
Intradigm Corporation |
Hpma-polyamine conjugates and uses therefore
|
AU2003205380A1
(en)
*
|
2002-02-01 |
2003-09-02 |
Intradigm Corporation |
Cationic polymers for use in therapeutic agent delivery
|
US7026465B2
(en)
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
WO2003087763A2
(en)
|
2002-04-03 |
2003-10-23 |
Celltech R & D, Inc. |
Association of polymorphisms in the sost gene region with bone mineral density
|
US20060193905A1
(en)
*
|
2002-05-14 |
2006-08-31 |
University Of Louisville Research Foundation, Inc. |
Direct cellular energy delivery system
|
CA2512108C
(en)
|
2003-01-06 |
2013-04-02 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
SI1625166T1
(sl)
|
2003-05-12 |
2015-08-31 |
Helion Biotech Aps |
Protitelesa masp-2
|
DE10322123A1
(de)
*
|
2003-05-12 |
2004-12-16 |
Novosom Ag |
Injizierbare Depots aus Liposomen und Polymeren zum Peptid- & Proteindelivery
|
EA015166B1
(ru)
*
|
2003-06-16 |
2011-06-30 |
Ю-Си-Би Мэньюфэкчуринг, Инк. |
Иммуногенные пептиды склеростина (sost), индуцирующие образование специфических антител
|
US9211248B2
(en)
|
2004-03-03 |
2015-12-15 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
TR201815364T4
(tr)
|
2004-03-03 |
2018-11-21 |
Revance Therapeutics Inc |
Botulinum toksinlerinin topikal uygulaması ve transdermal dağıtımı.
|
CA2558676C
(en)
|
2004-03-03 |
2019-04-16 |
Essentia Biosystems, Inc. |
Compositions and methods for topical diagnostic and therapeutic transport
|
CA2567597C
(en)
|
2004-05-25 |
2014-03-18 |
Oregon Health And Science University |
Siv and hiv vaccination using rhcmv-and hcmv-based vaccine vectors
|
US8840893B2
(en)
|
2004-06-10 |
2014-09-23 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
CA2573144C
(en)
|
2004-06-10 |
2014-07-22 |
Omeros Corporation |
Methods for treating conditions associated with masp-2 dependent complement activation
|
WO2005123776A1
(en)
*
|
2004-06-10 |
2005-12-29 |
Omeros Corporation |
Methods for treating conditions associated with lectin-dependent complement activation
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
MXPA06014731A
(es)
|
2004-06-14 |
2007-04-25 |
Zoser B Salama |
Composicion anticancerosa que comprende prolina o sus derivados y un anticuerpo antitumoral.
|
CA2597065C
(en)
|
2005-02-08 |
2014-10-14 |
Research Development Foundation |
Compositions and methods related to soluble g-protein coupled receptors (sgpcrs)
|
US8022179B2
(en)
*
|
2005-03-03 |
2011-09-20 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of an oligopeptide
|
WO2006094263A2
(en)
*
|
2005-03-03 |
2006-09-08 |
Revance Therapeutics, Inc. |
Compositions and methods for topical application and transdermal delivery of botulinum toxins
|
EA014527B1
(ru)
|
2005-03-31 |
2010-12-30 |
Глаксосмитклайн Байолоджикалс С.А. |
Вакцины против хламидиоза
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
PL1877426T3
(pl)
|
2005-04-29 |
2012-10-31 |
Glaxosmithkline Biologicals Sa |
Sposób profilaktyki lub leczenia zakażenia M. tuberculosis
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
US8003108B2
(en)
*
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
GB2430881B
(en)
*
|
2005-10-06 |
2010-10-13 |
Ntnu Technology Transfer As |
Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity
|
CN101355962A
(zh)
*
|
2005-11-17 |
2009-01-28 |
雷文斯治疗公司 |
减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法
|
WO2007062399A2
(en)
|
2005-11-23 |
2007-05-31 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
EP2441846A3
(de)
|
2006-01-09 |
2012-07-25 |
The Regents Of the University of California |
Immunstimulierende Kombinationen aus TNFRSF, TLR, NLR, RHR, purinergischem Rezeptor, und Zytokin-Rezeptor-Antagonisten für Impfstoffe und die Tumorimmuntherapie
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
EP2460828A3
(de)
*
|
2006-11-10 |
2012-08-08 |
UCB Pharma, S.A. |
Antikörper und Diagnose
|
EP2423226A3
(de)
|
2006-11-10 |
2012-05-30 |
Amgen Inc. |
Diagnose und Therapie auf Basis von Antikörpern
|
NZ598159A
(en)
*
|
2006-12-29 |
2013-08-30 |
Revance Therapeutics Inc |
Transport molecules using reverse sequence hiv-tat polypeptides
|
ES2599632T3
(es)
|
2007-04-09 |
2017-02-02 |
University Of Florida Research Foundation, Inc. |
Composiciones de vectores rAAV que tienen proteínas de la cápside modificadas en tirosina y métodos para su uso
|
GB0707096D0
(en)
*
|
2007-04-12 |
2007-05-23 |
Ntnu Technology Transfer As |
Method
|
EP2170384B1
(de)
|
2007-07-02 |
2016-04-13 |
Etubics Corporation |
Verfahren und zusammensetzungen zur herstellung eines adenovirus-vektors zur verwendung mit multiplen impfungen
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
CA2697373C
(en)
|
2007-08-27 |
2019-05-21 |
Longhorn Vaccines & Diagnostics, Llc |
Immunogenic compositions and methods
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
WO2009085355A2
(en)
|
2007-10-01 |
2009-07-09 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection and transport system and methods of use
|
UA97559C2
(uk)
*
|
2007-11-08 |
2012-02-27 |
Оцука Фармасьютікал Ко., Лтд. |
Комплекс нуклеїнової кислоти і композиція для доставки нуклеїнової кислоти
|
EP2227256A1
(de)
*
|
2007-12-14 |
2010-09-15 |
Amgen Inc. |
Verfahren zur behandlung von knochenbrüchen mit anti-sclerostin-antikörpern
|
EP2276727A1
(de)
*
|
2008-05-19 |
2011-01-26 |
The University of North Carolina At Chapel Hill |
Verfahren und zusammensetzungen mit neuartigen kationischen lipiden
|
GB0904942D0
(en)
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
GB0904941D0
(en)
|
2009-03-23 |
2009-05-06 |
Ntnu Technology Transfer As |
Composition
|
WO2010120541A2
(en)
|
2009-03-31 |
2010-10-21 |
University Of Washington |
Compositions and methods for modulating the activity of complement regulatory proteins on target cells
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
WO2011025905A1
(en)
|
2009-08-28 |
2011-03-03 |
Research Development Foundation |
Urocortin 2 analogs and uses thereof
|
AU2010306581B2
(en)
|
2009-10-16 |
2015-03-19 |
Omeros Corporation |
Methods for treating disseminated intravascular coagulation by inhibiting MASP-2 dependent complement activation
|
AU2010330794A1
(en)
|
2009-12-18 |
2012-06-21 |
Amgen Inc. |
Wise binding agents and epitopes
|
BR112012018669A2
(pt)
|
2010-01-27 |
2017-09-05 |
Glaxosmithkline Biologicals Sa |
Proteína rv3616c modificada, uso de uma proteína rv3616c modificada, polinucleotídeo, uso de um polinucleotídeo, composição farmacêutica, composição imunogênica, proteína de fusão, e, polipeptídeo.
|
EP3536781A1
(de)
|
2010-04-23 |
2019-09-11 |
University of Massachusetts |
Auf das zns abzielende vektoren und verfahren zur verwendung davon
|
JP2013533847A
(ja)
|
2010-04-23 |
2013-08-29 |
ユニバーシティ オブ マサチューセッツ |
コレステロール関連障害のaavベースの治療
|
ES2911185T3
(es)
|
2010-04-23 |
2022-05-18 |
Univ Florida |
Composiciones de rAAV-guanilato ciclasa y métodos para tratar la amaurosis congénita de Leber 1 (LCA1)
|
EP2386647A1
(de)
*
|
2010-05-10 |
2011-11-16 |
Qiagen GmbH |
Verfahren zur Transfektion einer eurkaryotischen Zelle
|
HUE033315T2
(en)
|
2010-05-14 |
2017-11-28 |
Amgen Inc |
High concentration antibody preparations
|
CA2798136C
(en)
|
2010-05-14 |
2019-06-04 |
Oregon Health & Science University |
Recombinant hcmv and rhcmv vectors and uses thereof
|
BR112013000391B8
(pt)
|
2010-07-06 |
2022-10-04 |
Novartis Ag |
Composição de emulsão catiônica de óleo em água e seu uso
|
CA2807552A1
(en)
|
2010-08-06 |
2012-02-09 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
ES2862955T3
(es)
|
2010-10-01 |
2021-10-08 |
Modernatx Inc |
Acidos nucleicos manipulados y métodos de uso de los mismos
|
WO2012113413A1
(en)
*
|
2011-02-21 |
2012-08-30 |
Curevac Gmbh |
Vaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
|
CN103649118A
(zh)
|
2011-03-01 |
2014-03-19 |
安进公司 |
双特异性结合剂
|
AU2012236962B2
(en)
|
2011-03-25 |
2017-05-11 |
Amgen Inc. |
Anti-sclerostin antibody crystals and formulations thereof
|
US8710200B2
(en)
|
2011-03-31 |
2014-04-29 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids encoding a modified erythropoietin and their expression
|
US9644035B2
(en)
|
2011-04-08 |
2017-05-09 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
EP3287142B1
(de)
|
2011-04-08 |
2021-08-04 |
University Of Leicester |
Verfahren zur behandlung von leiden in zusammenhang mit masp-2-abhängiger komplementaktivierung
|
CA2870511C
(en)
|
2011-04-21 |
2023-08-08 |
University Of Massachusetts |
Raav-based compositions and methods for treating alpha-1 anti-trypsin deficiencies
|
SI2704743T1
(sl)
|
2011-05-04 |
2020-08-31 |
Omeros Corporation |
Sestave za zaviranje sprožitve komplementov, odvisnih od masp-2
|
JP2014527398A
(ja)
|
2011-06-21 |
2014-10-16 |
オンコファクター コーポレイション |
がんの療法および診断のための組成物および方法
|
JP6059220B2
(ja)
|
2011-07-06 |
2017-01-18 |
ノバルティス アーゲー |
核酸を含む水中油型エマルジョン
|
CN103796639B
(zh)
|
2011-07-06 |
2017-05-31 |
诺华股份有限公司 |
阳离子水包油乳液
|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
WO2013019954A1
(en)
|
2011-08-04 |
2013-02-07 |
Amgen Inc. |
Method for treating bone gap defects
|
US9464124B2
(en)
|
2011-09-12 |
2016-10-11 |
Moderna Therapeutics, Inc. |
Engineered nucleic acids and methods of use thereof
|
WO2013052523A1
(en)
|
2011-10-03 |
2013-04-11 |
modeRNA Therapeutics |
Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
|
US9849087B2
(en)
|
2011-11-08 |
2017-12-26 |
The Board Of Trustees Of The University Of Arkansas |
Methods and compositions for X-ray induced release from pH sensitive liposomes
|
CN104114572A
(zh)
|
2011-12-16 |
2014-10-22 |
现代治疗公司 |
经修饰的核苷、核苷酸和核酸组合物
|
CA2858974A1
(en)
|
2011-12-28 |
2013-07-04 |
Amgen Inc. |
Method of treating alveolar bone loss through the use of anti-sclerostin antibodies
|
CA2863083C
(en)
|
2012-01-26 |
2023-09-19 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
AU2013243949A1
(en)
|
2012-04-02 |
2014-10-30 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of biologics and proteins associated with human disease
|
US9283287B2
(en)
|
2012-04-02 |
2016-03-15 |
Moderna Therapeutics, Inc. |
Modified polynucleotides for the production of nuclear proteins
|
US9572897B2
(en)
|
2012-04-02 |
2017-02-21 |
Modernatx, Inc. |
Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
|
US9878056B2
(en)
|
2012-04-02 |
2018-01-30 |
Modernatx, Inc. |
Modified polynucleotides for the production of cosmetic proteins and peptides
|
EP2833920A2
(de)
|
2012-04-02 |
2015-02-11 |
Moderna Therapeutics, Inc. |
Modifizierte polynukleotide zur herstellung von biologischen stoffen und proteinen in zusammenhang mit erkrankungen beim menschen
|
AU2013267909B2
(en)
|
2012-04-06 |
2018-03-01 |
Omeros Corporation |
Compositions and methods of inhibiting MASP-1, MASP-2 and/or MASP-3 for treatment of paroxysmal nocturnal hemoglobinuria
|
US20130344073A1
(en)
|
2012-06-18 |
2013-12-26 |
University Of Leicester |
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
|
EP3626267A1
(de)
|
2012-07-05 |
2020-03-25 |
UCB Pharma, S.A. |
Behandlung von knochenerkrankungen
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
PL2922554T3
(pl)
|
2012-11-26 |
2022-06-20 |
Modernatx, Inc. |
Na zmodyfikowany na końcach
|
EP2946014A2
(de)
|
2013-01-17 |
2015-11-25 |
Moderna Therapeutics, Inc. |
Signal-sensor-polynukleotide zur veränderung zellulärer phänotypen
|
CA2899889A1
(en)
|
2013-02-01 |
2014-08-07 |
Santa Maria Biotherapeutics, Inc. |
Administration of an anti-activin-a compound to a subject
|
US20160024181A1
(en)
|
2013-03-13 |
2016-01-28 |
Moderna Therapeutics, Inc. |
Long-lived polynucleotide molecules
|
US10258698B2
(en)
|
2013-03-14 |
2019-04-16 |
Modernatx, Inc. |
Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
|
BE1021939B1
(fr)
|
2013-03-15 |
2016-01-27 |
Glaxosmithkline Biologicals S.A. |
Composition pour des composes aminoalkylglucosaminide phosphate tamponnes et son utilisation.
|
EP2983687B1
(de)
|
2013-03-15 |
2019-09-04 |
The Regents of The University of California |
Peptide mit verminderter toxizität zur stimulation eines cholesterineffluxes
|
ES2825076T3
(es)
*
|
2013-03-15 |
2021-05-14 |
Rhythm Pharmaceuticals Inc |
Composiciones farmacéuticas
|
US8980864B2
(en)
|
2013-03-15 |
2015-03-17 |
Moderna Therapeutics, Inc. |
Compositions and methods of altering cholesterol levels
|
AU2014287009B2
(en)
|
2013-07-11 |
2020-10-29 |
Modernatx, Inc. |
Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
KR20160044566A
(ko)
|
2013-08-21 |
2016-04-25 |
큐어백 아게 |
호흡기 세포융합 바이러스
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US20160194368A1
(en)
|
2013-09-03 |
2016-07-07 |
Moderna Therapeutics, Inc. |
Circular polynucleotides
|
AU2014315287A1
(en)
|
2013-09-03 |
2015-03-12 |
Moderna Therapeutics, Inc. |
Chimeric polynucleotides
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
EP3052521A1
(de)
|
2013-10-03 |
2016-08-10 |
Moderna Therapeutics, Inc. |
Polynukleotide zur codierung von low-density-lipoprotein-rezeptor
|
BR112016008409B1
(pt)
|
2013-10-17 |
2021-06-15 |
Omeros Corporation E University Of Leicester |
Uso de um agente inibidor de masp-2 que inibe a ativação de complemento dependente de masp-2
|
KR102523466B1
(ko)
|
2013-11-07 |
2023-04-20 |
에디타스 메디신, 인코포레이티드 |
지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
|
KR102252561B1
(ko)
|
2013-11-22 |
2021-05-20 |
미나 테라퓨틱스 리미티드 |
C/ebp 알파 짧은 활성화 rna 조성물 및 사용 방법
|
US9068179B1
(en)
|
2013-12-12 |
2015-06-30 |
President And Fellows Of Harvard College |
Methods for correcting presenilin point mutations
|
US10280418B2
(en)
|
2014-03-18 |
2019-05-07 |
Univeristy Of Massachusetts |
RAAV-based compositions and methods for treating amyotrophic lateral sclerosis
|
SG11201608798YA
(en)
|
2014-04-23 |
2016-11-29 |
Modernatx Inc |
Nucleic acid vaccines
|
US10975391B2
(en)
|
2014-04-25 |
2021-04-13 |
University Of Massachusetts |
Recombinant AAV vectors useful for reducing immunity against transgene products
|
HRP20221536T1
(hr)
|
2014-06-25 |
2023-02-17 |
Acuitas Therapeutics Inc. |
Novi lipidi i formulacije lipidnih nanočestica za isporuku nukleinskih kiselina
|
EP3169310A1
(de)
|
2014-07-15 |
2017-05-24 |
Life Technologies Corporation |
Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
|
EP4159741A1
(de)
|
2014-07-16 |
2023-04-05 |
ModernaTX, Inc. |
Verfahren zur herstellung eines chimären polynukleotids zur kodierung eines polypeptids mit einer triazolhaltigen internukleotid-bindung
|
US20170210788A1
(en)
|
2014-07-23 |
2017-07-27 |
Modernatx, Inc. |
Modified polynucleotides for the production of intrabodies
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
US10029012B2
(en)
*
|
2014-09-05 |
2018-07-24 |
University Of Pittsuburgh—Of The Commonwealth System Of Higher Education |
Peptide-mediated intravesical delivery of therapeutic and diagnostic agents
|
US10711270B2
(en)
|
2014-10-03 |
2020-07-14 |
University Of Massachusetts |
High efficiency library-identified AAV vectors
|
EP3207150B1
(de)
|
2014-10-14 |
2021-04-28 |
Research Development Foundation |
Verfahren zur erzeugung von manipulierten enzymen
|
CN107073051B
(zh)
|
2014-10-21 |
2021-08-24 |
马萨诸塞大学 |
重组aav变体及其用途
|
EP3209780A4
(de)
|
2014-10-24 |
2018-09-19 |
University of Maryland, Baltimore |
Kurze nichtcodierende proteinregulatorische rnas (sprrnas) und verfahren zur verwendung
|
EP3212165B1
(de)
|
2014-10-30 |
2024-02-28 |
President and Fellows of Harvard College |
Freisetzung von negativ geladenen proteinen unter verwendung von kationischen lipiden
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
WO2016100575A1
(en)
|
2014-12-16 |
2016-06-23 |
Board Of Regents Of The University Of Nebraska |
Gene therapy for juvenile batten disease
|
WO2016100716A1
(en)
|
2014-12-18 |
2016-06-23 |
Vasant Jadhav |
Reversirtm compounds
|
CN107530383A
(zh)
|
2015-01-09 |
2018-01-02 |
埃图比克斯公司 |
用于埃博拉病毒疫苗接种的方法和组合物
|
EP3285788A4
(de)
|
2015-04-23 |
2018-12-05 |
University of Massachusetts |
Modulation der transgenexpression eines aav-vektors
|
EP3294448A4
(de)
|
2015-05-14 |
2018-12-12 |
Longhorn Vaccines and Diagnostics, LLC |
Schnellverfahren zur extraktion von nukleinsäuren aus biologischen proben
|
US9763892B2
(en)
|
2015-06-01 |
2017-09-19 |
Autotelic Llc |
Immediate release phospholipid-coated therapeutic agent nanoparticles and related methods
|
US10221127B2
(en)
|
2015-06-29 |
2019-03-05 |
Acuitas Therapeutics, Inc. |
Lipids and lipid nanoparticle formulations for delivery of nucleic acids
|
US11007260B2
(en)
|
2015-07-21 |
2021-05-18 |
Modernatx, Inc. |
Infectious disease vaccines
|
US11564893B2
(en)
|
2015-08-17 |
2023-01-31 |
Modernatx, Inc. |
Methods for preparing particles and related compositions
|
HRP20220156T1
(hr)
|
2015-09-17 |
2022-04-15 |
Modernatx, Inc. |
Spojevi i pripravci za unutarstaničnu isporuku terapeutskih sredstava
|
EP3362102A1
(de)
|
2015-10-14 |
2018-08-22 |
Life Technologies Corporation |
Ribonukleoprotein-transfektionsmittel
|
KR20180096593A
(ko)
|
2015-10-22 |
2018-08-29 |
모더나티엑스, 인크. |
단순 포진 바이러스 백신
|
CA3002820A1
(en)
|
2015-10-22 |
2017-04-27 |
Modernatx, Inc. |
Respiratory syncytial virus vaccine
|
TN2018000152A1
(en)
|
2015-10-22 |
2019-10-04 |
Modernatx Inc |
Nucleic acid vaccines for varicella zoster virus (vzv)
|
EP4011451A1
(de)
|
2015-10-22 |
2022-06-15 |
ModernaTX, Inc. |
Impfstoffe gegen atemwegsvirus
|
EP3364981A4
(de)
|
2015-10-22 |
2019-08-07 |
ModernaTX, Inc. |
Impfstoff gegen das humane cytomegalovirus
|
IL258821B
(en)
|
2015-10-23 |
2022-07-01 |
Harvard College |
Nucleobase editors and their uses
|
CN108472347B
(zh)
|
2015-11-09 |
2023-09-05 |
奥默罗斯公司 |
用于治疗与masp-2依赖性补体活化相关的病况的方法
|
SG11201804648RA
(en)
|
2015-12-04 |
2018-06-28 |
Univ Texas |
Slc45a2 peptides for immunotherapy
|
HRP20220652T1
(hr)
|
2015-12-10 |
2022-06-24 |
Modernatx, Inc. |
Pripravci i postupci unosa terapijskih sredstava
|
DK3394030T3
(da)
|
2015-12-22 |
2022-03-28 |
Modernatx Inc |
Forbindelser og sammensætninger til intracellulær afgivelse af midler
|
WO2017112943A1
(en)
|
2015-12-23 |
2017-06-29 |
Modernatx, Inc. |
Methods of using ox40 ligand encoding polynucleotides
|
KR102475622B1
(ko)
|
2016-01-05 |
2022-12-08 |
유니버시티 오브 레스터 |
필요로 하는 대상체에서 섬유증의 억제 방법
|
US20190241658A1
(en)
|
2016-01-10 |
2019-08-08 |
Modernatx, Inc. |
Therapeutic mRNAs encoding anti CTLA-4 antibodies
|
EP4094780A3
(de)
|
2016-02-12 |
2023-02-08 |
University of Massachusetts |
Anti-angiogene mirna-therapeutika zur hemmung der neovaskularisation der hornhaut
|
CN109154002B
(zh)
|
2016-03-01 |
2022-08-30 |
佛罗里达大学研究基金会有限公司 |
用于治疗显性视网膜色素变性的aav载体
|
KR102336362B1
(ko)
|
2016-03-03 |
2021-12-08 |
보이저 테라퓨틱스, 인크. |
비-바이러스 유전자 전달을 위한 폐쇄형-말단 선형 듀플렉스 dna
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
KR20200113290A
(ko)
|
2016-03-31 |
2020-10-06 |
오메로스 코포레이션 |
혈관 형성의 억제를 필요로 하는 대상체에서 혈관 형성을 억제하는 방법
|
PT3448364T
(pt)
|
2016-04-29 |
2022-05-04 |
Icahn School Med Mount Sinai |
Direcionamento do sistema imunitário inato para induzir uma tolerância a longo prazo e para resolver a acumulação de macrófagos na aterosclerose
|
US20190336608A1
(en)
*
|
2016-06-09 |
2019-11-07 |
Curevac Ag |
Cationic carriers for nucleic acid delivery
|
EP3468613A1
(de)
|
2016-06-09 |
2019-04-17 |
CureVac AG |
Hybride träger für nukleinsäuren
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
IL264565B1
(en)
|
2016-08-03 |
2024-03-01 |
Harvard College |
Adenosine nuclear base editors and their uses
|
CA3033327A1
(en)
|
2016-08-09 |
2018-02-15 |
President And Fellows Of Harvard College |
Programmable cas9-recombinase fusion proteins and uses thereof
|
US20190185864A1
(en)
|
2016-08-23 |
2019-06-20 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
US10457940B2
(en)
|
2016-09-22 |
2019-10-29 |
University Of Massachusetts |
AAV treatment of Huntington's disease
|
AU2017341849B2
(en)
|
2016-10-13 |
2024-03-21 |
University Of Massachusetts |
AAV capsid designs
|
JP2019530464A
(ja)
|
2016-10-14 |
2019-10-24 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
核酸塩基エディターのaav送達
|
WO2018089540A1
(en)
|
2016-11-08 |
2018-05-17 |
Modernatx, Inc. |
Stabilized formulations of lipid nanoparticles
|
IL266501B1
(en)
*
|
2016-11-10 |
2024-02-01 |
Translate Bio Inc |
An improved ICE-based lipid nanoparticle formulation for delivery of mRNA
|
US10745677B2
(en)
|
2016-12-23 |
2020-08-18 |
President And Fellows Of Harvard College |
Editing of CCR5 receptor gene to protect against HIV infection
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
CN110914310A
(zh)
|
2017-03-10 |
2020-03-24 |
哈佛大学的校长及成员们 |
胞嘧啶至鸟嘌呤碱基编辑器
|
ES2911186T3
(es)
|
2017-03-15 |
2022-05-18 |
Modernatx Inc |
Formas cristalinas de aminolípidos
|
RS63953B1
(sr)
|
2017-03-15 |
2023-02-28 |
Modernatx Inc |
Jedinjenje i kompozicije za intracelularnu isporuku terapeutskih sredstava
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
AU2018248304C1
(en)
|
2017-04-05 |
2023-02-16 |
University Of Massachusetts |
Minigene therapy
|
CN110799492B
(zh)
|
2017-04-28 |
2023-06-27 |
爱康泰生治疗公司 |
用于递送核酸的新型羰基脂质和脂质纳米颗粒制剂
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
EP4253544A3
(de)
|
2017-05-18 |
2023-12-20 |
ModernaTX, Inc. |
Modifizierte messenger-rna mit funktionellen rna-elementen
|
JP7285220B2
(ja)
|
2017-05-18 |
2023-06-01 |
モデルナティエックス インコーポレイテッド |
連結したインターロイキン-12(il12)ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子
|
MA49395A
(fr)
|
2017-06-14 |
2020-04-22 |
Modernatx Inc |
Polynucléotides codant pour le facteur viii de coagulation
|
WO2018232357A1
(en)
|
2017-06-15 |
2018-12-20 |
Modernatx, Inc. |
Rna formulations
|
EP3641794A4
(de)
|
2017-06-23 |
2021-03-24 |
The Trustees of Columbia University in the City of New York |
Verfahren zur prävention und behandlung von krankheiten, die durch synaptische dysfunktion und neurodegeneration gekennzeichnet sind, einschliesslich morbus alzheimer
|
WO2019023680A1
(en)
|
2017-07-28 |
2019-01-31 |
President And Fellows Of Harvard College |
METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
|
TWI818919B
(zh)
|
2017-08-15 |
2023-10-21 |
美商歐米諾斯公司 |
用於治療和/ 或預防與造血幹細胞移植有關的移植物抗宿主病和/ 或瀰漫性肺泡出血和/ 或靜脈閉塞性病的方法
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
EP3675817A1
(de)
|
2017-08-31 |
2020-07-08 |
Modernatx, Inc. |
Verfahren zur herstellung von lipidnanopartikeln
|
EP4219715A3
(de)
|
2017-09-08 |
2023-09-06 |
MiNA Therapeutics Limited |
Stabilisierte cebpa-sarna-zusammensetzungen und verfahren zur verwendung
|
EP4233880A3
(de)
|
2017-09-08 |
2023-09-20 |
MiNA Therapeutics Limited |
Hnf4a-sarna-zusammensetzungen und verfahren zur verwendung
|
WO2019079347A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
USES OF BASIC EDITORS ADENOSINE
|
US20210236644A1
(en)
|
2017-11-10 |
2021-08-05 |
Cocoon Biotech Inc. |
Ocular applications of silk-based products
|
JP7423521B2
(ja)
|
2017-11-22 |
2024-01-29 |
モダーナティエックス・インコーポレイテッド |
フェニルケトン尿症の治療用のフェニルアラニンヒドロキシラーゼをコードするポリヌクレオチド
|
WO2019104195A1
(en)
|
2017-11-22 |
2019-05-31 |
Modernatx, Inc. |
Polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits for the treatment of propionic acidemia
|
JP7423522B2
(ja)
|
2017-11-22 |
2024-01-29 |
モダーナティエックス・インコーポレイテッド |
尿素サイクル異常症の治療のためのオルニチントランスカルバミラーゼをコードするポリヌクレオチド
|
WO2019136241A1
(en)
|
2018-01-05 |
2019-07-11 |
Modernatx, Inc. |
Polynucleotides encoding anti-chikungunya virus antibodies
|
EP4169576A1
(de)
|
2018-03-23 |
2023-04-26 |
University of Massachusetts |
Gentherapeutika zur behandlung von knochenerkrankungen
|
KR20200138254A
(ko)
|
2018-03-30 |
2020-12-09 |
암젠 인크 |
C-말단 항체 변이체
|
WO2019200171A1
(en)
|
2018-04-11 |
2019-10-17 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements
|
US11566246B2
(en)
|
2018-04-12 |
2023-01-31 |
Mina Therapeutics Limited |
SIRT1-saRNA compositions and methods of use
|
EP3790607B1
(de)
|
2018-05-11 |
2023-12-27 |
Lupagen, Inc. |
Systeme für in sich geschlossene echtzeitänderungen von patientenzellen
|
GB2589246A
(en)
|
2018-05-16 |
2021-05-26 |
Synthego Corp |
Methods and systems for guide RNA design and use
|
WO2019226650A1
(en)
|
2018-05-23 |
2019-11-28 |
Modernatx, Inc. |
Delivery of dna
|
US11584714B2
(en)
|
2018-05-29 |
2023-02-21 |
Omeros Corporation |
MASP-2 inhibitors and methods of use
|
WO2020023390A1
(en)
|
2018-07-25 |
2020-01-30 |
Modernatx, Inc. |
Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
|
WO2020033791A1
(en)
|
2018-08-09 |
2020-02-13 |
Verseau Therapeutics, Inc. |
Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof
|
US20210170005A1
(en)
|
2018-08-15 |
2021-06-10 |
University Of Florida Research Foundation, Inc. |
Methods of sensitizing tumors to treatment with immune checkpoint inhibitors
|
US20220110966A1
(en)
|
2018-09-02 |
2022-04-14 |
Modernatx, Inc. |
Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency
|
US20220054610A1
(en)
|
2018-09-12 |
2022-02-24 |
University Of Florida Research Foundation, Inc. |
Slow-cycling cell-rna based nanoparticle vaccine to treat cancer
|
US20220243182A1
(en)
|
2018-09-13 |
2022-08-04 |
Modernatx, Inc. |
Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease
|
MA53609A
(fr)
|
2018-09-13 |
2021-07-21 |
Modernatx Inc |
Polynucléotides codant la glucose-6-phosphatase pour le traitement de la glycogénose
|
EP3850102A1
(de)
|
2018-09-14 |
2021-07-21 |
ModernaTX, Inc. |
Für die uridindiphosphat-glycosyltransferase-1-familie codierende polynukleotide, polypeptid a1 zur behandlung des crigler-najjar-syndroms
|
US20220047518A1
(en)
|
2018-09-19 |
2022-02-17 |
Moderna TX, Inc. |
Peg lipids and uses thereof
|
CA3113353A1
(en)
|
2018-09-19 |
2020-03-26 |
Modernatx, Inc. |
High-purity peg lipids and uses thereof
|
US20220152225A1
(en)
|
2018-09-27 |
2022-05-19 |
Modernatx, Inc. |
Polynucleotides encoding arginase 1 for the treatment of arginase deficiency
|
WO2020069339A1
(en)
|
2018-09-28 |
2020-04-02 |
President And Fellows Of Harvard College |
Mutant reverse tetracycline transactivators for expression of genes
|
CA3113472A1
(en)
|
2018-09-28 |
2020-04-02 |
President And Fellows Of Harvard College |
Cellular reprogramming to reverse aging and promote organ and tissue regeneration
|
WO2020097409A2
(en)
|
2018-11-08 |
2020-05-14 |
Modernatx, Inc. |
Use of mrna encoding ox40l to treat cancer in human patients
|
EP3887522A1
(de)
|
2018-11-29 |
2021-10-06 |
University of Massachusetts |
Modulation von sptlc1 über rekombinante adeno-assoziierte vektoren
|
WO2020146805A1
(en)
|
2019-01-11 |
2020-07-16 |
Acuitas Therapeutics, Inc. |
Lipids for lipid nanoparticle delivery of active agents
|
JP2022523055A
(ja)
|
2019-01-25 |
2022-04-21 |
シンテゴ コーポレイション |
Crispr活性をモジュレートするための系および方法
|
CA3131023A1
(en)
|
2019-02-22 |
2020-08-27 |
Michael R. Volkert |
Oxr1 gene therapy
|
WO2020191239A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
US20220211740A1
(en)
|
2019-04-12 |
2022-07-07 |
Mina Therapeutics Limited |
Sirt1-sarna compositions and methods of use
|
CA3137520A1
(en)
|
2019-04-24 |
2020-10-29 |
University Of Massachusetts |
Aav capsid chimeric antigen receptors and uses thereof
|
US20220218808A1
(en)
|
2019-05-02 |
2022-07-14 |
University Of Florida Research Foundation, Inc. |
Compositions for treatment of diffuse intrinsic pontine glioma
|
JP2022532078A
(ja)
|
2019-05-08 |
2022-07-13 |
アストラゼネカ アクチボラグ |
皮膚及び創傷のための組成物並びにその使用の方法
|
WO2020263985A1
(en)
|
2019-06-24 |
2020-12-30 |
Modernatx, Inc. |
Messenger rna comprising functional rna elements and uses thereof
|
EP3987027A1
(de)
|
2019-06-24 |
2022-04-27 |
ModernaTX, Inc. |
Endonukleaseresistente messenger-rna und verwendungen davon
|
EP4010031A1
(de)
|
2019-08-06 |
2022-06-15 |
L.E.A.F Holdings Group LLC |
Verfahren zur herstellung von polyglutamat-antifolaten und ihre verwendungen
|
CA3150458A1
(en)
|
2019-08-14 |
2021-02-18 |
Acuitas Therapeutics, Inc. |
Improved lipid nanoparticles for delivery of nucleic acids
|
US20220340643A1
(en)
|
2019-09-13 |
2022-10-27 |
Rutgers, The State University Of New Jersey |
Aav-compatible laminin-linker polymerization proteins
|
WO2021055833A1
(en)
|
2019-09-19 |
2021-03-25 |
Modernatx, Inc. |
Branched tail lipid compounds and compositions for intracellular delivery of therapeutic agents
|
KR20220110530A
(ko)
|
2019-12-04 |
2022-08-08 |
오메로스 코포레이션 |
Masp-2 억제자 및 사용 방법
|
WO2021168362A1
(en)
|
2020-02-21 |
2021-08-26 |
Akouos, Inc. |
Compositions and methods for treating non-age-associated hearing impairment in a human subject
|
US20230138409A1
(en)
|
2020-03-24 |
2023-05-04 |
Generation Bio Co. |
Non-viral dna vectors and uses thereof for expressing factor ix therapeutics
|
IL296662A
(en)
|
2020-03-24 |
2022-11-01 |
Generation Bio Co |
Non-viral DNA vectors and their use for expression of Gauche cure
|
IL296765A
(en)
|
2020-03-31 |
2022-11-01 |
Univ Massachusetts |
riants of aav capsids and their uses
|
CA3174187A1
(en)
|
2020-04-01 |
2021-10-07 |
University Of Florida Research Foundation, Incorporated |
Multilamellar rna nanoparticle vaccine against sars-cov-2
|
CA3181623A1
(en)
|
2020-04-29 |
2021-11-04 |
The Broad Institute, Inc. |
Machine learning accelerated protein engineering through fitness prediction
|
US20210346416A1
(en)
*
|
2020-05-05 |
2021-11-11 |
Ralph Lipp |
Pharmaceutical Compositions and Methods for their Use in Antiviral Therapy
|
DE112021002672T5
(de)
|
2020-05-08 |
2023-04-13 |
President And Fellows Of Harvard College |
Vefahren und zusammensetzungen zum gleichzeitigen editieren beider stränge einer doppelsträngigen nukleotid-zielsequenz
|
CA3178726A1
(en)
|
2020-05-21 |
2021-11-25 |
Gregory LIZEE |
T cell receptors with vgll1 specificity and uses thereof
|
JP2023527875A
(ja)
|
2020-06-01 |
2023-06-30 |
モダーナティエックス・インコーポレイテッド |
フェニルアラニンヒドロキシラーゼバリアント及びその使用
|
JP2023539574A
(ja)
|
2020-08-17 |
2023-09-15 |
マサチューセッツ インスティテュート オブ テクノロジー |
Shank3遺伝子治療アプローチ
|
US20230406895A1
(en)
|
2020-11-13 |
2023-12-21 |
Modernatx, Inc. |
Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis
|
WO2022120080A1
(en)
|
2020-12-03 |
2022-06-09 |
University Of Massachusetts |
Development of novel gene therapeutics for fibrodysplasia ossificans progressiva
|
US11524023B2
(en)
|
2021-02-19 |
2022-12-13 |
Modernatx, Inc. |
Lipid nanoparticle compositions and methods of formulating the same
|
JP2024511067A
(ja)
|
2021-03-19 |
2024-03-12 |
トレインド セラピューティクス ディスカバリー,インコーポレーテッド |
訓練された免疫を調節するための化合物およびその使用方法
|
EP4314260A1
(de)
|
2021-03-24 |
2024-02-07 |
Modernatx, Inc. |
Lipidnanopartikel und polynukleotide zur codierung von ornithintranscarbamylase zur behandlung von ornithintranscarbamylasemangel
|
WO2022204390A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof
|
WO2022204371A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof
|
WO2022204380A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof
|
WO2022204369A1
(en)
|
2021-03-24 |
2022-09-29 |
Modernatx, Inc. |
Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia
|
CA3214137A1
(en)
|
2021-03-26 |
2022-09-29 |
Mina Therapeutics Limited |
Tmem173 sarna compositions and methods of use
|
US20220325287A1
(en)
|
2021-03-31 |
2022-10-13 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
KR20240011714A
(ko)
|
2021-04-27 |
2024-01-26 |
제너레이션 바이오 컴퍼니 |
치료용 항체를 발현하는 비바이러스성 dna 벡터 및 이의 용도
|
WO2022232286A1
(en)
|
2021-04-27 |
2022-11-03 |
Generation Bio Co. |
Non-viral dna vectors expressing anti-coronavirus antibodies and uses thereof
|
KR20240017813A
(ko)
|
2021-05-10 |
2024-02-08 |
이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. |
신경질환 치료용 약학적 조성물
|
EP4355882A2
(de)
|
2021-06-15 |
2024-04-24 |
Modernatx, Inc. |
Manipulierte polynukleotide zur zelltyp- oder mikroumgebungsspezifischen expression
|
WO2022271776A1
(en)
|
2021-06-22 |
2022-12-29 |
Modernatx, Inc. |
Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome
|
WO2023056329A1
(en)
|
2021-09-30 |
2023-04-06 |
Akouos, Inc. |
Compositions and methods for treating kcnq4-associated hearing loss
|
WO2023056044A1
(en)
|
2021-10-01 |
2023-04-06 |
Modernatx, Inc. |
Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease
|
WO2023081526A1
(en)
|
2021-11-08 |
2023-05-11 |
Orna Therapeutics, Inc. |
Lipid nanoparticle compositions for delivering circular polynucleotides
|
WO2023095874A1
(ja)
*
|
2021-11-25 |
2023-06-01 |
国立大学法人長崎大学 |
脂質性化合物、リポソーム、エクソソーム、脂質ナノ粒子及びドラッグデリバリーシステム
|
WO2023099884A1
(en)
|
2021-12-01 |
2023-06-08 |
Mina Therapeutics Limited |
Pax6 sarna compositions and methods of use
|
CN114306641A
(zh)
*
|
2022-02-17 |
2022-04-12 |
大连民族大学 |
一种胆固醇氨基衍生物-蔗糖酯型阳离子脂质体/基因复合物及其制备方法
|
WO2023164545A1
(en)
|
2022-02-23 |
2023-08-31 |
Massachusetts Institute Of Technology |
Methods for upregulating shank3 expression
|
WO2023161350A1
(en)
|
2022-02-24 |
2023-08-31 |
Io Biotech Aps |
Nucleotide delivery of cancer therapy
|
WO2023170435A1
(en)
|
2022-03-07 |
2023-09-14 |
Mina Therapeutics Limited |
Il10 sarna compositions and methods of use
|
WO2023177655A1
(en)
|
2022-03-14 |
2023-09-21 |
Generation Bio Co. |
Heterologous prime boost vaccine compositions and methods of use
|
WO2023183909A2
(en)
|
2022-03-25 |
2023-09-28 |
Modernatx, Inc. |
Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia
|
WO2023196851A1
(en)
|
2022-04-06 |
2023-10-12 |
President And Fellows Of Harvard College |
Reversing aging of the central nervous system
|
WO2024026254A1
(en)
|
2022-07-26 |
2024-02-01 |
Modernatx, Inc. |
Engineered polynucleotides for temporal control of expression
|
WO2024040222A1
(en)
|
2022-08-19 |
2024-02-22 |
Generation Bio Co. |
Cleavable closed-ended dna (cedna) and methods of use thereof
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|